BTN3A1 and ovarian carcinoma: As mentioned above, targeting BTN3A1 with novel human antibodies that promote the formation of a complex of this butyrophilin with BTN2A1 elicited coordinated αβ and Vγ9Vδ2 T cell responses against established ovarian cancer xenografts, including orthotopic tumors [3].